Silk Therapeutics, Inc., a Boston, MA-based provider of silk protein solutions for human health and wellness, raised $2m in Series 1A financing.
The round is being led by The Kraft Group of Foxboro, Massachusetts. In conjunction with the funding, Daniel A. Kraft, Executive Vice President, The Kraft Group, is joining Silk Therapeutics’s board of directors.
The company intends to use the funds to launch its skincare line with initial rollout in the northeast and expanded efforts nationally and develop its patented natural silk technology in new markets beyond skincare.
Led by Greg Altman, PhD, Chief Executive Officer and co-investor, and and Rebecca Horan, PhD, Chief Operating Officer, Silk Therapeutics provides silk protein solutions for human health and wellness leveraging proprietary technology. Its line derives from pure, natural silk protein, rather than silk waste byproducts such as hydrolyzed silk, sericin, silk powder or genetically modified proteins.